Pancreatic enzyme replacement therapy (PERT) has revolutionized the management of digestive disorders like exocrine pancreatic insufficiency (EPI) and cystic fibrosis. This article delves into the distinctions between two widely prescribed PERT medications: Pancreaze and Creon. Gain valuable knowledge to make informed decisions, empowering both patients and healthcare professionals in selecting the most appropriate treatment for optimal health!
Active Ingredients
Both Pancreaze and Creon feature a mix of lipases, proteases, and amylases derived from pig pancreas. However, their precise composition and proportions can differ between the two medications.
The main ingredient in Pancreaze is pancrelipase, a mixture of digestive enzymes—lipases, proteases, and amylases—sourced from pig pancreas.
Similarly, Creon’s active ingredients are also extracted from pig pancreas, comprising lipases, proteases, and amylases. The exact composition and proportions of these enzymes can vary depending on the strength of the prescribed Creon medication.
-
Creon$97.99 – $166.99
Enzyme Strengths
Another crucial factor to consider is the enzyme strength offered by each medication. Pancreaze comes in various strengths to meet individual patient needs, with dosages ranging from 5000 to 42000 USP lipase units per capsule. Creon also provides a range of strengths, from 3000 to 36000 USP lipase units per capsule. The appropriate strength is determined by the severity of the patient’s condition and their response to treatment.
Administration
Both Pancreaze and Creon offer flexible administration options. They can be swallowed whole or sprinkled on soft, acidic foods like applesauce, making it easier for patients who have difficulty swallowing. It is essential to follow the specific administration instructions provided by the prescribing healthcare professional.
FDA Approval
Both Pancreaze and Creon have undergone rigorous clinical trials for FDA approval. Pancreaze was approved by the FDA in 2010, while Creon received its approval a year earlier in 2009. Both medications have demonstrated efficacy and safety in treating EPI and other related conditions.
Manufacturer
Pancreaze is produced by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, which is a renowned name in the healthcare industry. Creon is manufactured by AbbVie, another well-respected pharmaceutical company known for developing innovative therapies.
Availability and Cost
The prices of both Pancreaze and Creon can vary depending on the pharmacy location, insurance coverage, and available discounts or patient assistance programs. Here’s a general overview:
The cost of Pancreaze fluctuates, with the price for 2600 Pancreaze units (100 capsules) typically ranging from approximately $82 to $90 at various pharmacies across the United States.
Creon tends to be more expensive. On average, Creon (ranging from 6000 units to 30,000 units) costs about $218 for a supply of 100 capsules. Online Canadian Pharmacies like Bridge Health offer Creon in a price range of $84.37 – $144.41 for 100 capsules.
It is important to consult with a healthcare professional and check with your specific insurance provider or pharmacy for the most current and accurate pricing information.
Both Pancreaze and Creon are prescription medications, generally available at pharmacies in the United States with a valid prescription from a healthcare provider.